Published in Drug Week, April 1st, 2005
POZEN reported a net loss of $8.4 million, or $0.29 per share on a fully diluted basis, for the fourth quarter of 2004, compared to a net loss of $1.6 million, or $0.06 per share on a fully diluted basis, for the fourth quarter of 2003.
Revenue for the quarters ended December 31, 2004, and December 31, 2003 totaled $2.4 and $1.8 million, respectively. Revenue resulted from the amortization of upfront payments received in 2003 pursuant to collaboration agreements for MT 100, MT 300, and Trexima, and revenue earned for conducting additional U.S. Food and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.